Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT14 | O95848 | 3/20 | 0.62 |
| ▸ | NUDT5 | Q9UKK9 | 3/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.62 |
| ▸ | PRKDC | P78527 | 3/20 | 0.62 |
| ▸ | BTK | Q06187 | 11/20 | 0.50 |
| ▸ | LCK | P06239 | 7/20 | 0.50 |
| ▸ | LYN | P07948 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 6/20 | 0.47 |
| ▸ | TEK | Q02763 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29439185 | 0.99 | NUDT14 (0.61) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| Trifluoroacetic Acid SCHEMBL29836326 | 0.89 | NUDT14 (0.52) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL15613551 | 0.89 | LCK (0.52) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16931738 | 0.88 | NUDT14 (0.49) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL30387716 | 0.88 | PIK3CD (0.65) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL17626654 | 0.88 | NUDT14 (0.48) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL18235468 | 0.88 | KDR (0.49) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL12713498 | 0.88 | PIK3CD (0.50) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL12808147 | 0.88 | BTK (0.50) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL5065122 | 0.87 | PIK3CD (0.57) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 866 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-07-31 | — | — | US | claimed |
| EP-4509125-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | claimed |
| CN-114853764-B | Preparation process of ibutenib | 埃斯特维华义制药有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-115716832-A | Preparation method and application of ibrutinib impurity | 深圳鼎邦化学品有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-114853764-A | Preparation process of ibrutinib | 埃斯特维华义制药有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-111646998-B | Synthesis method of ibrutinib | 扬子江药业集团江苏紫龙药业有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-111116593-B | Continuous preparation method of imatinib | 河北合佳医药科技集团股份有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-111116593-A | Continuous and low-cost preparation method of imatinib | 河北合佳医药科技集团股份有限公司 | 2020-05-08 | — | — | CN | claimed |
| US-10626117-B2 | Process for the preparation of Ibrutinib | NATCO PHARMA LIMITED (IN) | 2020-04-21 | — | — | US | claimed |
| CN-109134472-B | Synthesis process of 3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidine-4-amine | 浙江理工大学 | 2020-02-11 | — | — | CN | claimed |
| US-20190241567-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF IBRUTINIB | NATCO PHARMA LIMITED (IN) | 2019-08-08 | — | — | US | claimed |
| US-20190040070-A1 | PROCESS FOR THE SYNTHESIS OF STABLE AMORPHOUS IBRUTINIB | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2019-02-07 | — | — | US | claimed |
| WO-2017163257-A1 | PROCESS FOR PREPARING PURE LH-PYRAZOLO[3,4-D] PYRIMIDINE DERIVATIVE | IND-SWIFT LABORATORIES LIMITED (IN) | 2017-09-28 | — | — | WO | claimed |
| WO-2017134684-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF IBRUTINIB | NATCO PHARMA LIMITED (IN) | 2017-08-10 | — | — | WO | claimed |
| WO-2017134588-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2017-08-10 | — | — | WO | claimed |
| WO-2016170545-A1 | PROCESS FOR THE PREPARATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENVL)-1H- PVRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPERIDINVL]-2-PROPEN-1-ONE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | NLRP3, NLRP1, CASP1 | NUDT14 1653/4885NUDT5 860/4885PIK3CD 4033/4885 |
| US-20190241567-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, BCL6B | NUDT14 2631/4885NUDT5 2165/4885PIK3CD 159/4885 |
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | NUDT14 4306/4885NUDT5 4775/4885PIK3CD 4821/4885 |
| US-20190040070-A1 | PROCESS FOR THE SYNTHESIS OF STABLE AMORPHOUS IBRUTINIB | BCL6B, BCL6, BCL9 | NUDT14 2161/4885NUDT5 2174/4885PIK3CD 413/4885 |
| US-10626117-B2 | Process for the preparation of Ibrutinib | BTK, SYK, BCL6B | NUDT14 2405/4885NUDT5 1925/4885PIK3CD 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.